Welcome to YHEC’s publication hub

Our latest research, all in one place. Browse our collection of journal articles, reports and conference proceedings to see how we’re contributing to HEOR research. Remember to: 

  • Filter by service, therapeutic area, or geography to narrow your results.
  • Search directly for keywords or specific titles to find what you need instantly.
Peer-reviewed publication

An Exploratory Cost-Effectiveness Analysis of a Novel Tissue Valve Compared with Mechanical Valves for Surgical Aortic Valve Replacement in Subgroups of People Aged 55–64 and 65+ with Aortic Stenosis in the UK

YHEC authors: Robert Malcolm, Ciara Buckley, Judith Shore, Angela Stainthorpe
Publication date: August 2023
Journal: Expert Review of Pharmacoeconomics and Outcomes Research

Abstract

OBJECTIVE: Exploratory analysis to conceptualize and evaluate the potential cost-effectiveness and economic drivers of using a novel tissue valve compared with mechanical heart valves for surgical aortic valve replacement (SAVR) in people aged 55-64 and 65+ with aortic stenosis (AS) from a National Health Service (NHS) UK perspective.

METHODS: A decision-analytic model was developed using a partitioned survival model. Parameter inputs were obtained from published literature. Deterministic and probabilistic sensitivity analyses (DSA and PSA) were conducted to explore the uncertainty around the parameters.

RESULTS: The novel tissue valve was potentially associated with higher quality-adjusted life years (QALYs) of 0.01 per person. Potential cost savings were greatest for those aged 55-64 (£408) versus those aged 65+(£53). DSA indicated the results to be most dependent on relative differences in general mortality, procedure costs, and reoperation rates. PSA estimated around 75% of the iterations to be cost-effective at £20,000 per QALY for those aged 55-64, and 57% for those aged 65+.

CONCLUSIONS: The exploratory analysis suggests that the novel tissue valve could be a cost-effective intervention for people over the age of 55 with AS who are suitable for SAVR in the UK.

Peer-reviewed publication

Economic Evaluation of 27,540 Patients with Mood and Anxiety Disorders and the Importance of Waiting Time and Clinical Effectiveness in Mental Healthcare

YHEC authors: Sam Harper, Robert Malcolm, Angela Stainthorpe
Publication date: August 2023
Journal: Nature Mental Health

Abstract

Understanding the drivers of health and economic cost for the treatment of mental health conditions is critical to meet the accelerating demands for care. We conducted an economic evaluation of real-world healthcare-systems data from 27,540 patients receiving care for a mood or an anxiety disorder within the UK National Healthcare Service. Using Markov models built on discrete health states to compare the cost-effectiveness of different interventions, we show that the principal drivers of healthcare cost relate to waiting times and treatment effectiveness. We find that internet-delivered cognitive behavioral therapy has a 'dominant' incremental cost-effectiveness ratio relative to standard care, offering similar clinical effectiveness but with shorter treatment times. In most healthcare systems, the clinical effectiveness of mental healthcare remains unquantified, and long treatment times are common. The potential for these findings to inform mental healthcare policy is substantial, particularly around immediacy of access and the importance of outcomes-focused quality management.

Peer-reviewed publication

Transarterial Therapies in Patients with Hepatocellular Carcinoma Eligible for Transarterial Embolization: A US Cost-Effectiveness Analysis

YHEC authors: Heather Davies, Tom Bromilow, Hannah Baker, Stuart Mealing, Hayden Holmes
Publication date: August 2023
Journal: Journal of Medical Economics

Abstract

OBJECTIVES: To assess the cost-effectiveness of transarterial radioembolization (TARE) versus conventional transarterial chemoembolization (cTACE) and drug-eluting beads chemoembolization (DEE-TACE) for patients with unresectable early- to intermediate-stage hepatocellular carcinoma (HCC).

DESIGN: A cohort-based Markov model with a five-year time horizon was developed to evaluate the cost-effectiveness of the three embolization treatments. Upon entering the model, patients with HCC received either TARE or one of the two other embolization treatments. Patients remained in a "watch and wait" state for tumor downstaging that allowed them to move to health states such as liver transplant, resection, systemic therapies, or cure. Clinical input parameters were retrieved from the published literature, and where values could not be sourced, assumptions were made and validated by clinical experts. Health benefits were quantified using quality-adjusted life years (QALYs). Cost input parameters were obtained from various sources, including the Medicare Cost Report, IBM® Micromedex RED BOOK, and published literature.

RESULTS: At five years, TARE was found to be cost-saving (saving $15,779 per person compared to cTACE) and produced 0.33 more QALYs per person than cTACE. TARE cost $13,696 more but produced 0.33 more QALYs than DEE-TACE, with an incremental cost-effectiveness ratio of $41,474 per QALY gained at five years. After accounting for parameter uncertainty, the likelihood of TARE being cost-effective was at least 90% against all comparators at a cost-effectiveness threshold of $100,000 per QALY gained.

CONCLUSIONS: TARE produces more QALYs than cTACE and DEE-TACE, with a high probability of being cost-effective against both comparators.

Peer-reviewed publication

Cost-Effectiveness of an Antibacterial Envelope for Infection Prevention in Patients Undergoing Cardiac Resynchronization Therapy Reoperations in Denmark

YHEC authors: Daniela Afonso, Stuart Mealing
Publication date: July 2023
Journal: EP Europace

Abstract

AIMS: Use of an absorbable antibacterial envelope during implantation prevents cardiac implantable electronic device infections in patients with a moderate-to-high infection risk. Previous studies demonstrated that an envelope is cost-effective in high-risk patients within German, Italian, and English healthcare systems, but these analyses were based on limited data and may not be generalizable to other healthcare settings.

METHODS AND RESULTS:
A previously published decision-tree-based cost-effectiveness model was used to compare the costs per quality-adjusted life year (QALY) associated with adjunctive use of an antibacterial envelope for infection prevention compared to standard-of-care intravenous antibiotics. The model was adapted using data from a Danish observational two-centre cohort study that investigated infection-risk patients undergoing cardiac resynchronization therapy (CRT) reoperations with and without an antibacterial envelope (n = 1943). We assumed a cost-effectiveness threshold of €34 125/QALY gained, based on the upper threshold used by the National Institute for Health and Care Excellence (£30 000). An antibacterial envelope was associated with an incremental cost-effectiveness ratio (ICER) of €12 022 per QALY in patients undergoing CRT reoperations, thus indicating that the envelope is cost-effective when compared with standard of care. A separate analysis stratified by device type showed ICERS of €6227 (CRT defibrillator) and €29 177 (CRT pacemaker) per QALY gained.

CONCLUSIONS: Cost-effectiveness ratios were favourable for patients undergoing CRT reoperations in the Danish healthcare system, and thus are in line with previous studies. Results from this study can contribute to making the technology available to Danish patients and align preventive efforts in the pacemaker and ICD area.

Peer-reviewed publication

I-PreFer Study: A Discrete Choice Experiment to Explore Patient, Caregiver and Pulmonologist Preferences of Idiopathic Pulmonary Fibrosis Pharmacological Treatment Options

YHEC authors: Tom Bromilow, Adam Smith, Stuart Mealing, Damian Lewis
Publication date: July 2023
Journal: Patient Preference and Adherence

Abstract

PURPOSE: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and ultimately fatal lung disease that, while rare, has seen incidence rise over time. There is no cure for IPF other than a lung transplant, though two antifibrotic (AF) drugs do exist to slow disease progression. While these drugs are efficacious, they are both associated with differing profiles of adverse events. This study aimed to elicit patient, caregiver and pulmonologist preferences on the treatment profiles of AFs via a discrete choice experiment (DCE).

PATIENTS AND METHODS: The DCE and associated survey were distributed across 7 European countries, and bespoke DCEs were developed for patients/caregivers and pulmonologists. After collaboration with European Pulmonary Fibrosis & Related Disorders Federation (EU-PFF) and expert pulmonologists, respectively, a patient/caregiver DCE with 5 attributes and a pulmonologist DCE with 6 attributes were finalized. The DCEs had a blocked approach to reduce participant burden and were distributed on an online survey platform. Preferences were estimated through conditional multinomial logit regression analysis.

RESULTS: Ninety-five patients, 22 caregivers and 115 pulmonologists fully completed their respective DCEs. Overall, patients and caregivers preferred management of treatment-related adverse events over both survival benefits and disease progression. Nearly all preference levels were found to be significantly different from their reference level. In contrast, pulmonologists showed a greater preference for control of lung function and exacerbations over adverse events. Although there were relative differences between the univariate subgroups in terms of the preference weights, most of these were not statistically significant.

CONCLUSION: The outcomes from this study suggest that while patients and caregivers had similar preferences for characteristics of IPF treatments, pulmonologists did not share those same preferences. Patients and caregivers preferred safety, while pulmonologists preferred efficacy. These differences should be considered by clinicians to better involve the patient in treatment decision-making for IPF.

Peer-reviewed publication

Machine Learning for Accelerating Screening in Evidence Reviews

YHEC authors: Mary Chappell, Mary Edwards, Deborah Watkins, Christopher Marshall, Sara Graziadio
Publication date: July 2023
Journal: Cochrane Evidence Synthesis and Methods

Abstract

Evidence reviews are important for informing decision-making and primary research, but they can be time-consuming and costly. With the advent of artificial intelligence, including machine learning, there is an opportunity to accelerate the review process at many stages, with study screening identified as a prime candidate for assistance. Despite the availability of a large number of tools promising to assist with study screening, these are not consistently used in practice and there is skepticism about their application. Single-arm evaluations suggest the potential for tools to reduce screening burden. However, their integration into practice may need further investigation through evaluations of outcomes such as overall resource use and impact on review findings and recommendations. Because the literature lacks comparative studies, it is not currently possible to determine their relative accuracy. In this commentary, we outline the published research and discuss options for incorporating tools into the review workflow, considering the needs and requirements of different types of review.

Report

[MTG 10006] Virtual Ward Platform Technologies for Acute Respiratory Infections: External Assessment Group Report

YHEC authors: Rachael McCool, Hayden Holmes, Lavinia Ferrante di Ruffano, Robert Malcolm, Paul Miller, Luc Curtis-Gretton, Joshua Bracewell, Emma Bishop
Publication date: June 2023
Publishers: National Insitute for Health and Care Excellence

Abstract

No abstract available.

1 … 25 26 27 28 29 … 83